Active Tumor Targeting: Active Targeting of Dendritic Polyglycerols for Diagnostic Cancer Imaging (Small 7/2020)

Pant, Kritee; Neuber, Christin; Zarschler, Kristof; Wodtke, Johanna; Meister, Sebastian; Haag, Rainer; Pietzsch, Jens; Stephan, Holger

doi:10.1002/smll.202070034

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, there is an urgent need to develop an intelligent, targeted nanoplatform as a “magic bullet” to precisely enhance RT-induced DNA damage with low side effects. One effective approach is to couple these therapeutic formulations with ligands (such as folate, Arg–Gly–Asp tripeptides, and/or hyaluronic acid) [ 23 – 25 ] or antibodies [ 26 – 28 ] that specifically recognize tumor cells or tumor vasculature-associated antigens. This would allow targeted delivery of drugs or radiosensitizers into tumor cells by ligand- or antibody-mediated enhanced endocytosis [ 29 ].…”

Section: Introductionmentioning

confidence: 99%

Dimeric Her2-specific affibody mediated cisplatin-loaded nanoparticles for tumor enhanced chemo-radiotherapy

et al. 2021

View full text Add to dashboard Cite

Background Solid tumor hypoxic conditions prevent the generation of reactive oxygen species (ROS) and the formation of DNA double-strand breaks (DSBs) induced by ionizing radiation, which ultimately contributes to radiotherapy (RT) resistance. Recently, there have been significant technical advances in nanomedicine to reduce hypoxia by facilitating in situ O2 production, which in turn serves as a “radiosensitizer” to increase the sensitivity of tumor cells to ionizing radiation. However, off-target damage to the tumor-surrounding healthy tissue by high-energy radiation is often unavoidable, and tumor cells that are further away from the focal point of ionizing radiation may avoid damage. Therefore, there is an urgent need to develop an intelligent targeted nanoplatform to enable precise enhanced RT-induced DNA damage and combined therapy. Results Human epidermal growth factor receptor 2 (Her2)-specific dimeric affibody (ZHer2) mediated cisplatin-loaded mesoporous polydopamine/MnO2/polydopamine nanoparticles (Pt@mPDA/MnO2/PDA-ZHer2 NPs) for MRI and enhanced chemo-radiotherapy of Her2-positive ovarian tumors is reported. These NPs are biodegradable under a simulated tumor microenvironment, resulting in accelerated cisplatin release, as well as localized production of O2. ZHer2, produced using the E. coli expression system, endowed NPs with Her2-dependent binding ability in Her2-positive SKOV-3 cells. An in vivo MRI revealed obvious T1 contrast enhancement at the tumor site. Moreover, these NPs achieved efficient tumor homing and penetration via the efficient internalization and penetrability of ZHer2. These NPs exhibited excellent inhibition of tumor growth with X-ray irradiation. An immunofluorescence assay showed that these NPs significantly reduced the expression of HIF-1α and improved ROS levels, resulting in radiosensitization. Conclusions The nanocarriers described in the present study integrated Her2 targeting, diagnosis and RT sensitization into a single platform, thus providing a novel approach for translational tumor theranostics. Graphic abstract

show abstract

Section: Introductionmentioning

confidence: 99%

Dimeric Her2-specific affibody mediated cisplatin-loaded nanoparticles for tumor enhanced chemo-radiotherapy

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Therefore, there is an urgent need to exploit an intelligently targeted nanoplatform as a magic bullet to precisely enhance RT-induced DNA damage with low side effects. One effective approach is to couple these therapeutic formulations with ligands (such as folate molecule, Arg-Gly-Asp tripeptide, and hyaluronic acid) [24][25][26] or antibodies [27][28][29] that speci cally recognize tumor cells or tumor vasculature associated antigens. This allows targeted delivery of drugs or radiosensitizers into tumor cells by ligand-or antibody-mediated enhanced endocytosis [30].…”

Section: Introductionmentioning

confidence: 99%

Dimeric Her2-Specific Affibody Mediated Cisplatin-Loaded Nanoparticles for Tumor Enhanced Chemo-Radiotherapy

Wang

Jia

Yuan

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: Solid tumor hypoxic conditions fails to facilitate reactive oxygen species (ROS) generation and formation of DNA double-strand breaks (DSBs) induced by ionizing radiation, ultimately lead to a crucial role in radiotherapy resistance. Recently, there have been significant technical advances in nanomedicine aid to relieve hypoxia by in situ production of O2, serving as “radiosensitizer” to induce tumor cells more sensitive to ionizing radiation. However, the off-target damage of surrounding healthy tissues caused by such high-energy radiation is often unavoidable and the tumor cells at some distance from the focal spot of ionizing radiation may avoid damage. Therefore, there is an urgent need to exploit an intelligently targeted nanoplatform to integrate both precisely enhance RT-induced DNA damage and combined therapy.Results: Herein, we developed human epidermal growth factor receptor 2 (Her2)-specific dimeric affibody (ZHer2) mediated cisplatin-loaded mesoporous polydopamine/MnO2/polydopamine nanoparticles (Pt@mPDA/MnO2/PDA-ZHer2 NPs) for MRI and enhanced chemo-radiotherapy of Her2-positive ovarian tumor. These NPs are biodegradable under simulated tumor microenvironment, resulting in cisplatin accelerated release, as well as production of O2. ZHer2 produced by the E. coli expression system endowed NPs with Her2-dependent binding ability in the Her2-positive SKOV-3 cells. In vivo MRI studies revealed an obvious T1 contrast enhancement at the tumor site. Moreover, these NPs achieved efficient tumor homing and penetration, attributing to the efficient internalization and penetrability of ZHer2. Under X-Ray irradiation, these NPs exhibited the highest tumor growth inhibition effect. Immunofluorescence assay showed these NPs significantly reduced the expression of HIF-1α and improved ROS level, resulting in radiosensitization. Conclusions: The nanocarriers constructed in this study integrated Her2 targeting, diagnosis, RT sensitization, thus providing a new idea for clinical translation in tumor theranostics.

show abstract

Application of bismuth sulfide based nanomaterials in cancer diagnosis and treatment

Yang¹,

Wang²,

Zhang³

et al. 2023

Chin. Sci. Bull.

View full text Add to dashboard Cite

Active Tumor Targeting: Active Targeting of Dendritic Polyglycerols for Diagnostic Cancer Imaging (Small 7/2020)

Cited by 3 publications

References 0 publications

Dimeric Her2-specific affibody mediated cisplatin-loaded nanoparticles for tumor enhanced chemo-radiotherapy

Dimeric Her2-specific affibody mediated cisplatin-loaded nanoparticles for tumor enhanced chemo-radiotherapy

Dimeric Her2-Specific Affibody Mediated Cisplatin-Loaded Nanoparticles for Tumor Enhanced Chemo-Radiotherapy

Application of bismuth sulfide based nanomaterials in cancer diagnosis and treatment

Contact Info

Product

Resources

About

Active Tumor Targeting: Active Targeting of Dendritic Polyglycerols for Diagnostic Cancer Imaging (Small 7/2020)

Cited by 3 publications

References 0 publications

Dimeric Her2-specific affibody mediated cisplatin-loaded nanoparticles for tumor enhanced chemo-radiotherapy

Dimeric Her2-specific affibody mediated cisplatin-loaded nanoparticles for tumor enhanced chemo-radiotherapy

Dimeric&nbsp;Her2-Specific Affibody Mediated Cisplatin-Loaded Nanoparticles for Tumor Enhanced Chemo-Radiotherapy

Application of bismuth sulfide based nanomaterials in cancer diagnosis and treatment

Contact Info

Product

Resources

About

Dimeric Her2-Specific Affibody Mediated Cisplatin-Loaded Nanoparticles for Tumor Enhanced Chemo-Radiotherapy